使用同调K分布超声检测伴肝脂肪变性个体的肝纤维化
本研究基于237例患者构建同调K分布α参数图,并按组织学METAVIR纤维化评分与脂肪变性程度分组,与声学结构定量ASQ的FD比值比较。结果显示HK α参数随纤维化分期升高而单调下降(p < .05),FD比值升高(p < .05);在显著脂肪变性组(II组,n=64)HK成像对各期纤维化的AUROC为0.91、0.81、0.76、0.73,优于ASQ;ASQ在I组未能表征肝纤维化。作者推荐HK成像用于显著肝脂肪变性患者早期纤维化风险评估。
要点
- HK α参数随肝纤维化分期加重而单调下降,FD比值则升高,两者变化均p < .05。
- 中重度脂肪变性组(II组)HK α诊断≥F1、≥F2、≥F3、≥F4的AUROC分别为0.91、0.81、0.76、0.73。
- I组(正常至轻度脂肪变性)ASQ的FD比值未能表征肝纤维化,HK α与FD比值AUROC相近(0.55–0.68)。
核心结论
- HK α参数随肝纤维化分期增加而单调下降(p < .05),FD比值随分期增加而升高(p < .05)。
- 与既往研究不同,ASQ在I组(正常至轻度脂肪变性)未能表征肝纤维化。
- HK成像在合并中重度肝脂肪变性患者早期检出肝纤维化的诊断性能优于ASQ。
- 作者推荐将超声HK成像作为评估显著肝脂肪变性患者早期纤维化风险的策略。
研究设计与样本
- 研究纳入患者n = 237,采集原始超声图像数据构建B模式图与HK α参数图。
- 以组织学证据(METAVIR纤维化评分与肝脂肪变性严重程度)为参考标准,并与ASQ获得的FD比值比较。
- 数据分为I组(n = 173;正常至轻度肝脂肪变性)与II组(n = 64;中度至重度肝脂肪变性)。
- 统计分析采用单因素方差分析与受试者工作特征(ROC)曲线分析。
关键影像表现/征象
- HK α参数图基于同调K分布参数α构建,并与B模式图对照。
- 随肝纤维化分期增加,HK α参数单调下降(p < .05)。
- 随肝纤维化分期增加,ASQ的FD比值升高(p < .05)。
诊断标准与关键数值
- I组诊断≥F1、≥F2、≥F3、≥F4的AUROC:FD比值分别为0.56、0.68、0.64、0.62,α参数分别为0.55、0.68、0.64、0.62。
- II组诊断≥F1、≥F2、≥F3、≥F4的AUROC:FD比值分别为0.88、0.81、0.77、0.78,α参数分别为0.91、0.81、0.76、0.73。
- 纤维化分期依据METAVIR纤维化评分,脂肪变性程度依据组织学肝脂肪变性严重程度分级。
临床应用与阅片要点
- 对合并中重度肝脂肪变性的患者,可采用HK α参数成像评估早期肝纤维化风险(作者推荐)。
- 在正常至轻度肝脂肪变性人群中,ASQ的FD比值未能表征肝纤维化,HK α与FD比值诊断性能相近。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Acoustic structure quantification (ASQ) based on the analysis of ultrasound backscattered statistics has been reported to detect liver fibrosis without significant hepatic steatosis. This study proposed using ultrasound parametric imaging based on the parameter α of the homodyned K (HK) distribution for staging liver fibrosis in patients with significant hepatic steatosis. Raw ultrasound image data were acquired from patients (n = 237) to construct B-mode and HK α parametric images, which were compared with the focal disturbance (FD) ratio obtained from ASQ on the basis of histologic evidence (METAVIR fibrosis score and hepatic steatosis severity). The data were divided into group I (n = 173; normal to mild hepatic steatosis) and group II (n = 64; with moderate to severe hepatic steatosis) for statistical analysis through one-way analysis of variance and receiver operating characteristic (ROC) curve analysis. The results showed that the HK α parameter monotonically decreased as the liver fibrosis stage increased (p < .05); concurrently, the FD ratio increased (p < .05). For group I, the areas under the ROC (AUROCs) obtained using the FD ratio and the α parameter (AUROCFD and AUROCα) were, respectively, 0.56 and 0.55, 0.68 and 0.68, 0.64 and 0.64 and 0.62 and 0.62 for diagnosing liver fibrosis ≥F1, ≥F2, ≥F3 and ≥F4. The values of AUROCFD and AUROCα for group II were, respectively, 0.88 and 0.91, 0.81 and 0.81, 0.77 and 0.76 and 0.78 and 0.73 for diagnosing liver fibrosis ≥F1, ≥F2, ≥F3 and ≥F4. As opposed to previous studies, ASQ was found to fail in characterizing liver fibrosis in group I; however, it was workable for identifying liver fibrosis in patients with significant hepatic steatosis (group II). Compared with ASQ, HK imaging provided improved diagnostic performance in the early detection of liver fibrosis coexisting with moderate to severe hepatic steatosis. Ultrasound HK imaging is recommended as a strategy to evaluate early fibrosis risk in patients with significant hepatic steatosis.
引用
- Tsai YW, Zhou Z, Gong CA, et al. Ultrasound Detection of Liver Fibrosis in Individuals with Hepatic Steatosis Using the Homodyned K Distribution. Ultrasound Med Biol. 2020. PMID: 33109381. doi:10.1016/j.ultrasmedbio.2020.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。